2012|13 Annual Report Fraunhofer IGB

63 Dr. Iris Trick Phone +49 711 970-4217 iris.trick@igb.fraunhofer.de Dr. Michaela Müller Phone +49 711 970-4140 michaela.mueller@igb.fraunhofer.de Funding We would like to thank the German Federal Ministry of Education and Research (BMBF) and the French National Research Agency (ANR) for funding the project “BioCapabili” within the joint project “Inter Carnot Fraunhofer PICF 2009”. Project partner CIRIMAT Carnot Institute | ENSIACET, 4 allée. Emile Monso, 31030 Toulouse cedex 4 France | * Dr. Christophe Drouet, christophe.drouet@ensiacet.fr (number of re-cultivable cells)). A high starting cell count of between 107 cells/ml for Staphylococci and 109 cells/ml for E. coli and P. aeruginosa was reached on silver and bismuth- doped CaP apatite in high-concentration screening. The re- duction factor RF shown in the diagram speciﬁes the reduction in viable and reproductive cells in logarithm form. The maxi- mum possible value corresponds to the number of starting cells used and therefore the total inactivation of the cells was accomplished. It was possible to fully inactivate the Staphylo- cocci with the levels of doping shown. E. coli and P. aerugi- nosa show no impairment at 0.1 percent silver (RF =0),w hile at only 0.5 percent silver both bismuth concentrations were equally fully inactivated. Preliminary in vivo implantation tests were launched at the end of the project to investigate the potential impact of the best formulations on osteogenesis. Outlook With a view to future developments, we were able to estab- lish contact with surgeons and industrial companies during the course of the project and a patent for one of the new for- mulations has been ﬁled. A number of industrial companies have shown serious interest in this patent and in the French- German BioCapabili research alliance. Both institutes have identiﬁed several further novel applications for the antibacte- rial materials – as the foundation for long-term collaboration in the development of antibacterial materials in Europe. 1 Specimen of the biomimetic bone replacement material (source: CIRIMAT Carnot Institute). 2 Microscopy image of the apatite used (source: CIRIMAT Carnot Institute). 3 Screening to quantify the antimicrobial properties of the BioCapabili formulations. 0 ReductionfactorRF 0.1 % silver 0.5 % silver 0.1 % bismuth 0.5 % bismuth 9 8 7 6 5 4 3 2 1 S. aureus E. coli P. aeruginosa S. epidermidis 4 5 4 Scanning electron microscope image of a bioﬁlm of the species Staphylococcus aureus on the surface of nanocrystalline calcium phosphate apatite (without antimicrobial properties) from the CIRIMAT Institute. 5 Antibacterial effect of various BioCapabili formulations on rel- evant bacterial strains. Contacts

2012|13 Annual Report Fraunhofer IGB

Pages